论文部分内容阅读
目的:研究n 131I治疗对分化型甲状腺癌(differentiated thyroid cancer, DTC)患者的甲状旁腺素(parathyroid hormone, PTH)的影响。n 方法:收集了初始PTH(基线PTH)和血钙正常并接受n 131I治疗的353例(男性121例，女性232例)DTC患者的临床数据，询问患者n 131I治疗后是否有手足抽搐、四肢麻木或感觉异常等。比较n 131I治疗前后的PTH、血钙和血磷的变化。根据患者的性别、年龄、病理类型、美国癌症联合委员会(American Joint Committee on Cancer, AJCC)分期、服碘剂量和残留甲状腺组织，进一步分析PTH的变化在其中的影响。采用配对n t检验和Pearson n χ2检验进行统计。n 结果:所有患者在n 131I治疗后均未出现手足抽搐、四肢麻木或感觉异常等低血钙症状。在n 131I治疗后，PTH明显下降[(39.83±16.94)μg/L对(36.98±16.31)μg/L, n P<0.01]，血钙轻微下降[(2.30±0.12)mmol/L对(2.27±0.14)mmol/L,n P<0.01]。PTH变化在性别、年龄、病理类型、AJCC分期、服碘剂量和残留甲状腺组织中差异均无统计学意义。n 结论:DTC患者在n 131I治疗后PTH轻度下降，并无低血钙症状发生。PTH的变化与患者性别、年龄、病理类型、AJCC分期、服碘剂量和残留甲状腺组织没有关系。n “,”Objective:This study aimed to investigate the influence of n 131I therapy on parathyroid hormone (PTH) in differentiated thyroid cancer (DTC) patients.n Methods:Clinical data were collected from 353 DTC patients (121 males and 232 females) with normal initial PTH (baseline PTH) and normal serum calcium who received n 131I therapy, and tetany, limbs anesthesia, or paresthesia after the n 131I therapy were also collected. Comparisons were performed on the changes of PTH, serum calcium, and serum phosphorus before and after n 131I therapy. According to gender, age, histology, American Joint Committee on Cancer (AJCC) stages, administered activity, and residual thyroid tissue, further analyses were done for the difference of changes of PTH. Paired t-tests and Pearson χ n 2 test were used to conduct statistics.n Results:No patients suffered from tetany, limbs anesthesia, or paresthesia, etc. PTH showed a significant decrease [(39.83±16.94)μg/Ln vs (36.98±16.31)μg/L,n P<0.01] after then 131I therapy. Serum calcium also decreased mildly [(2.30±0.12)mmol/L n vs (2.27±0.14)mmol/L, n P<0.01]. There was no significant difference in changes of PTH in gender, age, histology, AJCC stages, administered activity, and residual thyroid tissue.n Conclusions:PTH of DTC patients decreased mildly after n 131I therapy, and no hypocalcemia occurred. The change of PTH was not associated with sex, age, histology, AJCC stages, administered activity, and residual thyroid tissue.n